Dynavax Technologies (DVAX) Earning Somewhat Favorable News Coverage, Report Finds

News articles about Dynavax Technologies (NASDAQ:DVAX) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dynavax Technologies earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.0666133493603 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the headlines that may have impacted Accern Sentiment’s scoring:

Several research analysts have recently weighed in on DVAX shares. Royal Bank of Canada reiterated an “outperform” rating and set a $28.00 price target (up previously from $26.00) on shares of Dynavax Technologies in a research note on Monday, September 25th. Cowen reiterated a “buy” rating and set a $30.00 price target on shares of Dynavax Technologies in a research note on Friday, November 3rd. BidaskClub cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. ValuEngine cut shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, Cantor Fitzgerald lifted their price target on shares of Dynavax Technologies from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $25.17.

Dynavax Technologies (DVAX) opened at $18.60 on Tuesday. Dynavax Technologies has a one year low of $3.70 and a one year high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.15. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The company had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.28 million. During the same quarter in the previous year, the company earned ($0.90) EPS. Dynavax Technologies’s revenue for the quarter was down 68.8% on a year-over-year basis. analysts expect that Dynavax Technologies will post -1.72 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/12/12/dynavax-technologies-dvax-earning-somewhat-favorable-news-coverage-report-finds.html.

About Dynavax Technologies

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Insider Buying and Selling by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply